Real world evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)

Trial Identifier: D3250R00101
Sponsor: AstraZeneca
NCTID:: NCT05271526
Start Date: May 2022
Primary Completion Date: November 2023
Study Completion Date: November 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia Moscow, Russia, 105077